These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 16528410)

  • 1. Identification and characterization of noncalcemic, tissue-selective, nonsecosteroidal vitamin D receptor modulators.
    Ma Y; Khalifa B; Yee YK; Lu J; Memezawa A; Savkur RS; Yamamoto Y; Chintalacharuvu SR; Yamaoka K; Stayrook KR; Bramlett KS; Zeng QQ; Chandrasekhar S; Yu XP; Linebarger JH; Iturria SJ; Burris TP; Kato S; Chin WW; Nagpal S
    J Clin Invest; 2006 Apr; 116(4):892-904. PubMed ID: 16528410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-activity relationship of nonsecosteroidal vitamin D receptor modulators.
    Yamada S; Makishima M
    Trends Pharmacol Sci; 2014 Jul; 35(7):324-37. PubMed ID: 24865943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel nonsecosteroidal vitamin D mimics exert VDR-modulating activities with less calcium mobilization than 1,25-dihydroxyvitamin D3.
    Boehm MF; Fitzgerald P; Zou A; Elgort MG; Bischoff ED; Mere L; Mais DE; Bissonnette RP; Heyman RA; Nadzan AM; Reichman M; Allegretto EA
    Chem Biol; 1999 May; 6(5):265-75. PubMed ID: 10322128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Current Topics on Vitamin D. Nonsecosteroidal vitamin D mudulators and prospects for their thepapeutic application].
    Makishima M
    Clin Calcium; 2015 Mar; 25(3):403-11. PubMed ID: 25716814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Noncalcemic actions of vitamin D receptor ligands.
    Nagpal S; Na S; Rathnachalam R
    Endocr Rev; 2005 Aug; 26(5):662-87. PubMed ID: 15798098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vitamin D analogs: mechanism of action and therapeutic applications.
    Nagpal S; Lu J; Boehm MF
    Curr Med Chem; 2001 Nov; 8(13):1661-79. PubMed ID: 11562285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vitamin D receptor as a drug discovery target.
    Pinette KV; Yee YK; Amegadzie BY; Nagpal S
    Mini Rev Med Chem; 2003 May; 3(3):193-204. PubMed ID: 12570835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vitamin D receptor modulators for inflammation and cancer.
    Yee YK; Chintalacharuvu SR; Lu J; Nagpal S
    Mini Rev Med Chem; 2005 Aug; 5(8):761-78. PubMed ID: 16101412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of cellular environment on the selective activation of the vitamin D receptor by 1alpha,25-dihydroxyvitamin D3 and its analog 1alpha-fluoro-16-ene-20-epi-23-ene-26,27-bishomo-25-hydroxyvitamin D3 (Ro-26-9228).
    Ismail A; Nguyen CV; Ahene A; Fleet JC; Uskokovic MR; Peleg S
    Mol Endocrinol; 2004 Apr; 18(4):874-87. PubMed ID: 14726489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic applications for novel non-hypercalcemic vitamin D receptor ligands.
    Choi M; Makishima M
    Expert Opin Ther Pat; 2009 May; 19(5):593-606. PubMed ID: 19441936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel nonsecosteroidal VDR ligands with phenyl-pyrrolyl pentane skeleton for cancer therapy.
    Ge Z; Hao M; Xu M; Su Z; Kang Z; Xue L; Zhang C
    Eur J Med Chem; 2016 Jan; 107():48-62. PubMed ID: 26562542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vitamin D receptor ligands for osteoporosis.
    Cheskis BJ; Freedman LP; Nagpal S
    Curr Opin Investig Drugs; 2006 Oct; 7(10):906-11. PubMed ID: 17086935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of triple bond and adamantane ring on the vitamin D side chain produced partial agonists for vitamin D receptor.
    Kudo T; Ishizawa M; Maekawa K; Nakabayashi M; Watarai Y; Uchida H; Tokiwa H; Ikura T; Ito N; Makishima M; Yamada S
    J Med Chem; 2014 May; 57(10):4073-87. PubMed ID: 24773565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 1,25-Dihydroxyvitamin D3 stimulates cyclic vitamin D receptor/retinoid X receptor DNA-binding, co-activator recruitment, and histone acetylation in intact osteoblasts.
    Kim S; Shevde NK; Pike JW
    J Bone Miner Res; 2005 Feb; 20(2):305-17. PubMed ID: 15647825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vitamin D receptor agonists: opportunities and challenges in drug discovery.
    Takahashi T; Morikawa K
    Curr Top Med Chem; 2006; 6(12):1303-16. PubMed ID: 16848744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence for tissue- and cell-type selective activation of the vitamin D receptor by Ro-26-9228, a noncalcemic analog of vitamin D3.
    Peleg S; Ismail A; Uskokovic MR; Avnur Z
    J Cell Biochem; 2003 Feb; 88(2):267-73. PubMed ID: 12520525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene regulatory potential of nonsteroidal vitamin D receptor ligands.
    Peräkylä M; Malinen M; Herzig KH; Carlberg C
    Mol Endocrinol; 2005 Aug; 19(8):2060-73. PubMed ID: 15860548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The importance of stereochemistry on the actions of vitamin D.
    Chiellini G; DeLuca HF
    Curr Top Med Chem; 2011; 11(7):840-59. PubMed ID: 21291397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vitamin D receptor activation reduces VCaP xenograft tumor growth and counteracts ERG activity despite induction of TMPRSS2:ERG.
    Roberts JM; Martin RS; Piyarathna DB; MacKrell JG; Rocha GV; Dodge JA; Coarfa C; Krishnan V; Rowley DR; Weigel NL
    Oncotarget; 2017 Jul; 8(27):44447-44464. PubMed ID: 28591703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin-like growth factor binding protein-5 interacts with the vitamin D receptor and modulates the vitamin D response in osteoblasts.
    Schedlich LJ; Muthukaruppan A; O'Han MK; Baxter RC
    Mol Endocrinol; 2007 Oct; 21(10):2378-90. PubMed ID: 17595320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.